Candriam S.C.A. Grows Position in IQVIA Holdings Inc. $IQV

Candriam S.C.A. raised its position in IQVIA Holdings Inc. (NYSE:IQV) by 61.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 272,747 shares of the medical research company’s stock after purchasing an additional 103,567 shares during the quarter. Candriam S.C.A. owned 0.16% of IQVIA worth $51,806,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of IQV. Verdence Capital Advisors LLC bought a new stake in shares of IQVIA in the 2nd quarter valued at about $3,612,000. Amundi increased its holdings in IQVIA by 46.3% during the second quarter. Amundi now owns 1,279,817 shares of the medical research company’s stock valued at $210,722,000 after buying an additional 405,250 shares during the period. Diversified Trust Co raised its stake in IQVIA by 57.2% in the third quarter. Diversified Trust Co now owns 42,579 shares of the medical research company’s stock worth $8,087,000 after buying an additional 15,487 shares in the last quarter. Nichols & Pratt Advisers LLP MA lifted its holdings in IQVIA by 8.6% during the third quarter. Nichols & Pratt Advisers LLP MA now owns 122,603 shares of the medical research company’s stock worth $23,287,000 after buying an additional 9,684 shares during the period. Finally, Act Two Investors LLC bought a new stake in IQVIA during the 2nd quarter valued at $26,528,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Up 3.6%

NYSE:IQV opened at $187.50 on Monday. The company has a current ratio of 0.75, a quick ratio of 0.70 and a debt-to-equity ratio of 2.09. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $247.04. The company has a market cap of $31.93 billion, a PE ratio of 23.85, a P/E/G ratio of 1.90 and a beta of 1.37. The company’s 50 day moving average is $228.03 and its two-hundred day moving average is $209.87.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping the consensus estimate of $3.40 by $0.02. The business had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Jefferies Financial Group decreased their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research note on Friday. Mizuho set a $266.00 price target on shares of IQVIA in a research report on Friday, January 9th. Evercore restated an “outperform” rating and issued a $225.00 price target on shares of IQVIA in a report on Thursday. BMO Capital Markets set a $250.00 price objective on shares of IQVIA in a research note on Friday. Finally, Stifel Nicolaus lowered their target price on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research note on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and a consensus target price of $241.75.

Key Stories Impacting IQVIA

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: Q4 results beat consensus: IQV reported Q4 EPS of $3.42 and revenue of $4.36B, both above estimates and showing double‑digit Y/Y sales growth — a core reason buyers are stepping in. IQVIA Holdings (IQV) Q4 Earnings and Revenues Top Estimates
• Positive Sentiment: FY‑2026 guidance modestly raised on revenue and EPS ranges (EPS 12.55–12.85; revenue $17.2B–$17.4B) — guidance came in around or slightly above Street revenue/consensus EPS, supporting near‑term sentiment. IQVIA’s (NYSE:IQV) Q4 CY2025 Sales Top Estimates
• Positive Sentiment: Jefferies lowered its price target to $255 but kept a “buy” rating — that still implies sizable upside vs. the current price and helps underpin demand from buy‑side holders. Jefferies PT Cut (Benzinga)
• Neutral Sentiment: Citigroup trimmed its price target to $200 and moved to “neutral” — a calibration of expectations but not a full sell signal. Citigroup PT Change (Benzinga)
• Neutral Sentiment: Analyst commentary and value‑style writeups (Zacks) highlight IQV as a longer‑term value play based on style scores — useful for longer‑horizon investors rather than short‑term movers. Why IQVIA Is a Top Value Stock (Zacks)
• Negative Sentiment: IQV warned that higher interest expenses will weigh on annual profit, and Reuters notes the company forecast annual profit below Street expectations — this is increasing focus on leverage and interest‑rate sensitivity. IQV Forecasts Weak Annual Profit (Reuters)
• Negative Sentiment: Market headlines flagged that shares fell after management’s outlook for adjusted earnings missed some expectations — that knee‑jerk reaction pressured the stock before buyers re‑entered. Shares Down After Outlook Misses (MarketWatch)
• Negative Sentiment: BTIG cut its rating to neutral citing sector headwinds — another signal that some sell‑side shops are taking a more cautious near‑term stance. BTIG Cuts Rating to Neutral (MSN)

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.